Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
CNY 25.56
(1.43%)
CNY 25.56
(1.43%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 675.67 Million CNY | 28.74% |
| 2022 | 603.34 Million CNY | 5.62% |
| 2021 | 571.23 Million CNY | -4.91% |
| 2020 | 600.75 Million CNY | -21.67% |
| 2019 | 766.93 Million CNY | 8.27% |
| 2018 | 708.32 Million CNY | 100.09% |
| 2017 | 354 Million CNY | 143.2% |
| 2016 | 145.55 Million CNY | -36.79% |
| 2015 | 230.27 Million CNY | -33.23% |
| 2014 | 344.86 Million CNY | -24.44% |
| 2013 | 456.38 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 140.54 Million CNY | 9.73% |
| 2024 Q1 | 128.07 Million CNY | -47.77% |
| 2024 Q3 | 173.5 Million CNY | 22.02% |
| 2023 FY | 776.72 Million CNY | 28.74% |
| 2023 Q3 | 176.02 Million CNY | -4.07% |
| 2023 Q2 | 183.5 Million CNY | 57.05% |
| 2023 Q1 | 116.84 Million CNY | -35.13% |
| 2023 Q4 | 245.21 Million CNY | 39.31% |
| 2022 Q2 | 151.12 Million CNY | 38.69% |
| 2022 Q1 | 108.96 Million CNY | -42.14% |
| 2022 FY | 603.34 Million CNY | 5.62% |
| 2022 Q4 | 180.12 Million CNY | 10.42% |
| 2022 Q3 | 163.12 Million CNY | 7.94% |
| 2021 Q2 | 177.65 Million CNY | 38.68% |
| 2021 Q1 | 128.1 Million CNY | -35.43% |
| 2021 Q3 | 77.15 Million CNY | -56.57% |
| 2021 Q4 | 188.31 Million CNY | 144.06% |
| 2021 FY | 571.23 Million CNY | -4.91% |
| 2020 FY | 600.75 Million CNY | -21.67% |
| 2020 Q4 | 198.38 Million CNY | 29.17% |
| 2020 Q2 | 203.35 Million CNY | 347.57% |
| 2020 Q1 | 45.43 Million CNY | -79.03% |
| 2020 Q3 | 153.57 Million CNY | -24.48% |
| 2019 Q3 | 164.97 Million CNY | -31.1% |
| 2019 Q1 | 145.86 Million CNY | -31.19% |
| 2019 FY | 766.93 Million CNY | 8.27% |
| 2019 Q4 | 216.63 Million CNY | 31.31% |
| 2019 Q2 | 239.45 Million CNY | 64.16% |
| 2018 Q2 | 217.32 Million CNY | 67.41% |
| 2018 FY | 708.32 Million CNY | 100.09% |
| 2018 Q4 | 211.96 Million CNY | 41.98% |
| 2018 Q3 | 149.29 Million CNY | -31.3% |
| 2018 Q1 | 129.81 Million CNY | -6.99% |
| 2017 FY | 354 Million CNY | 143.2% |
| 2017 Q3 | 86.55 Million CNY | 0.0% |
| 2017 Q4 | 139.57 Million CNY | 61.25% |
| 2016 FY | 145.55 Million CNY | -36.79% |
| 2015 FY | 230.27 Million CNY | -33.23% |
| 2014 FY | 344.86 Million CNY | -24.44% |
| 2013 FY | 456.38 Million CNY | 0.0% |